Connection

Anders Sönnerborg to HIV-1

This is a "connection" page, showing publications Anders Sönnerborg has written about HIV-1.
Connection Strength

2.940
  1. A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort. BMC Infect Dis. 2019 Jul 01; 19(1):569.
    View in: PubMed
    Score: 0.268
  2. Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. PLoS One. 2018; 13(7):e0200505.
    View in: PubMed
    Score: 0.250
  3. Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing. Sci Rep. 2018 05 15; 8(1):7556.
    View in: PubMed
    Score: 0.248
  4. Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. AIDS. 2018 04 24; 32(7):877-884.
    View in: PubMed
    Score: 0.247
  5. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018 02 20; 32(4):469-476.
    View in: PubMed
    Score: 0.244
  6. Prediction of coreceptor usage by five bioinformatics tools in a large Ethiopian HIV-1 subtype C cohort. PLoS One. 2017; 12(8):e0182384.
    View in: PubMed
    Score: 0.236
  7. Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden. Sci Rep. 2017 07 25; 7(1):6371.
    View in: PubMed
    Score: 0.234
  8. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. PLoS One. 2017; 12(6):e0178942.
    View in: PubMed
    Score: 0.232
  9. Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses-an analysis of a prospective country-wide cohort. BMC Infect Dis. 2017 01 06; 17(1):37.
    View in: PubMed
    Score: 0.225
  10. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. J Med Virol. 2009 Jan; 81(1):1-8.
    View in: PubMed
    Score: 0.129
  11. MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors. Viruses. 2019 08 30; 11(9).
    View in: PubMed
    Score: 0.068
  12. Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. J Antimicrob Chemother. 2018 10 01; 73(10):2721-2728.
    View in: PubMed
    Score: 0.064
  13. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathog. 2018 04; 14(4):e1006973.
    View in: PubMed
    Score: 0.062
  14. Prophylaxis and treatment of HIV-1 infection in pregnancy - Swedish Recommendations 2017. Infect Dis (Lond). 2018 07; 50(7):495-506.
    View in: PubMed
    Score: 0.061
  15. Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells. Front Immunol. 2018; 9:19.
    View in: PubMed
    Score: 0.061
  16. Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet. 1997 Dec 20-27; 350(9094):1823.
    View in: PubMed
    Score: 0.060
  17. Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. J Infect Dis. 2017 11 27; 216(9):1063-1069.
    View in: PubMed
    Score: 0.060
  18. A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 T-cell decline trajectory model. HIV Med. 2017 10; 18(9):677-684.
    View in: PubMed
    Score: 0.058
  19. Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy. Sci Rep. 2017 04 06; 7(1):666.
    View in: PubMed
    Score: 0.057
  20. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014 Jul 21; 14:407.
    View in: PubMed
    Score: 0.048
  21. Microfluidic centrifugation assisted precipitation based DNA quantification. Lab Chip. 2019 04 23; 19(9):1657-1664.
    View in: PubMed
    Score: 0.017
  22. Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. Int J Antimicrob Agents. 2018 May; 51(5):733-738.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.